Led · Equity · Apr 2026

Founded in 2017 and headquartered in the UK, Paysend operates a global digital payments network that connects more than 25 billion endpoints and serves over 12 million customers. The platform supports cross-border transactions in more than 170 countries and has reported increasing payment volumes as it scales internationally. Paysend offers products for both consumers and enterprises and continues to expand its product suite. The company emphasizes development of proprietary technology to underpin its network and product roadmap. Recent funding from an existing investor is intended to accelerate geographic expansion and product launches. Claret Capital cited Paysend’s scalable infrastructure and execution against growth plans as reasons for the follow-on investment.

Led · Equity · Oct 2025

Yseop is a generative AI specialist focused on life sciences, offering an enterprise platform that automates the writing of complex documents such as clinical study reports, patient narratives and CMC submissions. Its flagship product, Yseop Copilot, is already deployed at major pharmaceutical companies including Eli Lilly and Novartis. The system uses a Composite AI architecture that blends large language models with business logic and domain rules to deliver scientifically aligned, audit-ready content. Native integrations with Microsoft Word and Veeva Vault let users embed automation directly into existing workflows, accelerating document production while maintaining compliance. With regulatory demands growing, the company sees rising demand for intelligent automation across the sector. The newly secured funding will be used to scale global adoption, enhance product capabilities and accelerate innovation. Although detailed operating metrics such as revenue were not disclosed, the presence of blue-chip customers underscores early commercial traction.

Led · Debt Financing · Oct 2025

Deciphex, founded in 2017 and headquartered on Dublin City University’s Alpha campus, offers two core products: Diagnexia, which links a global pool of subspecialty pathologists for rapid case turnaround, and Patholytix, which streamlines preclinical safety assessments in drug development. These platforms collectively manage more than 97,000 cases per year through a network of 250+ pathologists. The company employs roughly 220 people across sites in Dublin, Exeter, Oxford, Chicago and Toronto, and it already serves customers in the EU, UK, US, Canada and Japan. Deciphex’s technology focuses on replacing manual, repetitive histopathology processes with AI-driven workflows to deliver faster, more reliable diagnoses. The firm aims to become the leading histopathology reporting provider in the UK by 2027 while simultaneously building a significant U.S. presence. Recognition of its execution includes being named the Irish Medtech Association’s Medtech Company of the Year in 2023. Recent financings—€31 m Series C equity followed by €15 m in venture debt—provide resources for continued international expansion.

Led · Debt Financing · Aug 2025

Mindler operates an online psychology platform providing digital access to mental health care. The company has been expanding in the UK, where revenues grew by over 60% last year and where Mindler has focused on children and youth. Mindler reported SEK 267 million in revenue last year and halved its loss to SEK 50 million. The company plans both organic growth and continued consolidation through acquisitions. Mindler is acquiring UK competitor Ieso and will merge the two platforms under the Mindler brand. Management says the deal and additional funding will support both short- and long-term growth plans. Mindler operates a smartphone app that enables patients to consult with a psychologist within 24 hours. The platform currently employs over 200 accredited psychologists who meet with patients remotely. Though the company is active in just two countries, its clinicians cover 20 languages. Mindler was founded in 2018 and is based in Stockholm, operating in Sweden and the Netherlands. The startup recently raised an €8 million Series A to fund expansion. Management says the funding will be used to introduce the app in new parts of Europe to increase access to psychological care outside metropolitan areas.

Participated · Series E · Mar 2025

Cardiac Dimensions develops minimally invasive treatments for heart failure and functional mitral regurgitation, with its flagship Carillon Mitral Contour System designed as a catheter-based therapy to restore natural mitral valve function. The Carillon device aims to reduce mitral regurgitation, improve quality of life, and has been associated in clinical studies with extended survival; it can be used as a front-line option and does not preclude future therapies. The company says the procedure promotes favorable left ventricular remodeling while avoiding damage to mitral valve leaflets. Cardiac Dimensions plans to use new financing to complete the EMPOWER Trial U.S. pivotal study and to continue commercialization and global commercial expansion of the Carillon therapy. The company recently closed an oversubscribed $53 million Series E financing led by Ally Bridge Group with significant participation from existing investors. Cardiac Dimensions has operations in Kirkland, Washington; Sydney, Australia; and Frankfurt, Germany. Cardiac Dimensions develops the Carillon Mitral Contour System, a minimally invasive, non-surgical device intended to restore mitral valve function and induce favorable left ventricular remodeling to reduce mitral regurgitation. The Carillon therapy is an indirect, no-touch annuloplasty designed to improve quality of life and extend survival and can be used alongside other heart-failure treatments. The device has obtained CE Mark and Therapeutic Goods Approval (TGA) and is approved for sale in Europe and Australia, while it is considered an investigational device in the U.S. To date, thousands of patients have been treated with the Carillon system worldwide, and positive safety and performance data encompassing more than 350 patients have been published from four studies and a real-world registry. Cardiac Dimensions is currently enrolling the U.S. EMPOWER pivotal trial and intends to use new financing to accelerate enrollment, broaden treatment to earlier-stage patients, and expand commercial sales in European markets with full reimbursement. The company has operations in Kirkland, Washington; Sydney, Australia; and Frankfurt, Germany. Cardiac Dimensions develops minimally invasive treatments for functional mitral regurgitation (FMR), centered on its Carillon Mitral Contour System®. The Carillon System uses a right-heart, transcatheter approach via the coronary sinus to reshape the mitral apparatus. The device is CE-marked (0344) and has been implanted in over 1,200 patients across the U.S., Europe, Australia, Turkey and the Middle East. The company is studying the device in the pivotal CARILLON Trial and it remains investigational in the United States. Management, led by CEO Rick Wypych, plans to accelerate commercial sales in Europe and expand into other geographies such as Australia. Recent regulatory progress includes approval from Australia’s Therapeutic Goods Administration for commercial use in FMR patients with mild to severe mitral regurgitation. The company closed a $17.5M Series C to support these commercial efforts. Cardiac Dimensions develops the Carillon Mitral Contour System, a minimally invasive, catheter-based device intended to treat functional mitral regurgitation by reducing the dilated mitral annulus. The company is building clinical evidence through multiple studies, including completing follow-up and publication of the randomized, double-blinded REDUCE FMR global study and continuing enrollment in The CARILLON U.S. pivotal trial. The Carillon System has CE Mark clearance and is available in certain European markets, including Turkey, the Netherlands and Italy. More than 850 patients worldwide have been treated with the device across completed international studies (AMADEUS, TITAN, TITAN II) and ongoing trials. Cardiac Dimensions intends to use new financing to support continued trial enrollment, complete the REDUCE FMR follow-up/publication, and expand its presence in global markets. The company has operations in Kirkland, Sydney and Frankfurt. Cardiac Dimensions develops minimally invasive treatment modalities for heart failure and related cardiovascular conditions, with an initial technology platform called the CARILLON Mitral Contour System designed to address functional mitral regurgitation via a percutaneous approach. The company is led by CEO Rick Stewart and is based in Kirkland, Washington; Sydney, Australia; and Frankfurt, Germany. It raised an additional $15.2M in this financing, bringing total capital raised to $43M. Proceeds are planned to fund the REDUCE FMR blinded, randomized clinical trial of a percutaneous mitral repair device in patients with functional mitral regurgitation. The company also intends to expand research and development projects and its commercial operations with the new funding.